Cresco Labs Inc. (CSE: CL)
CL trades on the Canadian Securities Exchange in Life Sciences, headquartered in British Columbia. Numbers below come from the TMX issuer list, Yahoo Finance closes and the Bank of Canada rate, each with its source.
Issuer list, sector and C$ market cap: TMX Group TSX and TSXV listed companies, as of November 13, 2026. US$ figures convert C$ at 1.4257 C$ per US$, the Bank of Canada daily rate for November 13, 2026. Close and returns: Yahoo Finance daily closes for CL.CN, last bar 2026-11-13, computed by MarginsX. Website: sociallinks: 40-F text ("our website").
Profile
| Field | Value |
|---|---|
| Ticker | CL on the Canadian Securities Exchange |
| Yahoo symbol | CL.CN |
| Sector | Life Sciences, Drug Manufacturers—Specialty & Generic |
| Headquarters | British Columbia |
| Listed | The TMX list gives no listing date |
| Listing type | TMX leaves listing type blank for long-listed issuers |
| Shares outstanding | 502,755,064 |
| Also listed on | No interlisting on the TMX list |
| Index membership | Not in an S&P/TSX index per the TMX list |
| SEC CIK | 0001832928 |
| Website | www.crescolabs.com |
Returns
| Window | Return |
|---|---|
| 1 day | +4.3% |
| 1 week | -8.9% |
| 1 month | -20.0% |
| 3 months | -34.5% |
| 6 months | -43.3% |
| Year to date | -56.6% |
| 1 year | -52.0% |
| From 52-week high | -73.5% |
| 52-week range | C$0.6900 to C$2.72 |
Links
SEDAR+ is linked for searching only; nothing on this page is taken from it.
Recent Canadian filings by type
69 documents in 11 types. Each title links to the document at its source.
Annual financial statements (2)
| Document | Type | Filed |
|---|---|---|
| Audited consolidated financial statements of the Company and notes thereto as at and for the years ended December 31, 2025 and 2024, together with… Period 2025-12-31 | Annual financial statements (40-F) | 2026-03-06 |
| Audited consolidated financial statements of the Company and notes thereto as at and for the years ended December 31, 2024 and 2023, together with… Period 2024-12-31 | Annual financial statements (40-F) | 2025-03-14 |
Interim financial statements (9)
| Document | Type | Filed |
|---|---|---|
| Unaudited Condensed Interim Consolidated Financial Statements for the three and nine months ended September 30, 2026 and 2025 Period 2026-09-30 | Interim financial statements (6-K) | 2026-11-06 |
| Request for Financial Statements | Interim financial statements (6-K) | 2026-09-30 |
| Unaudited Condensed Interim Consolidated Financial Statements for the three and six months ended June 30, 2026 and 2025 Period 2026-06-30 | Interim financial statements (6-K) | 2026-08-06 |
| Unaudited Condensed Interim Consolidated Financial Statements for the three months ended March 31, 2026 and 2025 Period 2026-03-31 | Interim financial statements (6-K) | 2026-05-08 |
MD&A (9)
| Document | Type | Filed |
|---|---|---|
| Management’s Discussion and Analysis of Financial Condition and Results of Operations for the years ended December 31, 2025 and 2024 Period 2025-12-31 | MD&A (annual) (40-F) | 2026-03-06 |
| Management’s Discussion and Analysis of Financial Condition and Results of Operations for the years ended December 31, 2024 and 2023 Period 2024-12-31 | MD&A (annual) (40-F) | 2025-03-14 |
| Management Discussion and Analysis of Financial Condition and Results of Operations for the three and nine months ended September 30, 2026 and 2025 Period 2026-09-30 | MD&A (interim) (6-K) | 2026-11-06 |
| Management Discussion and Analysis of Financial Condition and Results of Operations for the three and six months ended June 30, 2026 and 2025 Period 2026-06-30 | MD&A (interim) (6-K) | 2026-08-06 |
Annual information form (2)
| Document | Type | Filed |
|---|---|---|
| Annual Information Form of the Company for the year ended December 31, 2025 Period 2025-12-31 | Annual information form (40-F) | 2026-03-06 |
| Annual Information Form of the Company for the year ended December 31, 2024 Period 2024-12-31 | Annual information form (40-F) | 2025-03-14 |
News release (14)
| Document | Type | Filed |
|---|---|---|
| News Release dated November 6, 2026 | News release (6-K) | 2026-11-06 |
| News Release dated November 2, 2026 | News release (6-K) | 2026-11-03 |
| News Release dated August 6, 2026 | News release (6-K) | 2026-08-06 |
| News Release dated May 8, 2026 | News release (6-K) | 2026-05-08 |
Management information circular / proxy (9)
| Document | Type | Filed |
|---|---|---|
| Supplement Dated October 9, 2026 to the Management Information Circular of the Corporation dated September 18, 2026, prepared in connection with its… | Management information circular (6-K) | 2026-10-13 |
| Management Information Circular of the Corporation dated September 18, 2026, prepared in connection with its annual general and special meeting of… | Management information circular (6-K) | 2026-09-30 |
| Management Information Circular of the Corporation dated August 11, 2025, prepared in connection with an annual general meeting of shareholders held… | Management information circular (6-K) | 2025-08-15 |
| Notice of Availability of Proxy Materials for Cresco Labs Inc. Annual General and Special Meeting Period 2025-12-31 | Notice of meeting (6-K) | 2026-09-30 |
Prospectus (2)
| Document | Type | Filed |
|---|---|---|
| F-10 | Prospectus (short form) (F-10) | 2025-10-06 |
| Prospectus Supplement dated January 29, 2026 | Prospectus supplement (6-K) | 2026-02-02 |
Annual report (2)
| Document | Type | Filed |
|---|---|---|
| 40-F Period 2025-12-31 | Annual report (40-F) (40-F) | 2026-03-06 |
| 40-F Period 2024-12-31 | Annual report (40-F) (40-F) | 2025-03-14 |
Early warning / ownership (3)
| Document | Type | Filed |
|---|---|---|
| Schedule 13G amendment | Schedule 13G (SCHEDULE 13G/A) | 2025-05-15 |
| Schedule 13G | Schedule 13G (SCHEDULE 13G) | 2025-02-14 |
| Schedule 13G amendment | Schedule 13G (SC 13G/A) | 2024-11-14 |
Certification (6)
| Document | Type | Filed |
|---|---|---|
| Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act… Period 2025-12-31 | Certification (SOX 302/906) (40-F) | 2026-03-06 |
| Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act… Period 2025-12-31 | Certification (SOX 302/906) (40-F) | 2026-03-06 |
| Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section 1350, as… Period 2025-12-31 | Certification (SOX 302/906) (40-F) | 2026-03-06 |
| Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act… Period 2024-12-31 | Certification (SOX 302/906) (40-F) | 2025-03-14 |
Other (11)
| Document | Type | Filed |
|---|---|---|
| Consent of Marcum LLP Period 2025-12-31 | Consent (40-F) | 2026-03-06 |
| Consent of Baker Tilly, LLP Period 2025-12-31 | Consent (40-F) | 2026-03-06 |
| EX-5.1 | Consent (F-10) | 2025-10-06 |
| EX-5.2 | Consent (F-10) | 2025-10-06 |
Sources: SEC EDGAR filings (public records). Documents filed only on SEDAR+ are not copied here; search SEDAR+ for the full record.
Trading halts
Trading: the last notice, on 2025-12-18, was a resumption.
| Notice | Action | Reason | Notice |
|---|---|---|---|
| 2025-12-18 1:07:03 PM ET | Resumption | No reason stated | CIRO notice |
| 2025-12-18 1:02:03 pm ET | Halt | Single Stock Circuit Breaker | CIRO notice |
| 2025-10-15 12:53:39 PM ET | Resumption | No reason stated | CIRO notice |
| 2025-10-15 12:48:39 PM ET | Halt | Single Stock Circuit Breaker | CIRO notice |
| 2025-08-29 10:02:47 AM ET | Resumption | No reason stated | CIRO notice |
| 2025-08-29 9:57:47 AM ET | Halt | Single Stock Circuit Breaker | CIRO notice |
Source: Canadian Investment Regulatory Organization (CIRO), Halts/Resumptions newsroom, notices since 2024-10-15.
Upcoming events
No upcoming earnings date, call or meeting announced in the SEC filings and newswire releases we read.
Recent
| Date | Time | Event | Webcast | Source |
|---|---|---|---|---|
| 2026-11-06 | No time in the announcement | Q3 2026 earnings release | No webcast link announced | SEC filing |
| 2026-11-06 | 8:30am Eastern Time | Q3 2026 earnings call | Webcast | SEC filing |
Source: dates read from the company's SEC filings and newswire releases; each row links to the announcement.
US private placements (SEC Form D)
| Filed | Securities | Sold | Offered | Filing |
|---|---|---|---|---|
| 2021-12-21 | Equity | US$62.1M | US$62.1M | SEC EDGAR |
| 2018-10-23 | Equity | US$100.0M | US$100.0M | SEC EDGAR |
| 2018-10-19 | Equity | US$100.0M | US$100.0M | SEC EDGAR |
| 2014-10-06 | Equity | US$4.0M | US$4.0M | SEC EDGAR |
Source: SEC EDGAR Form D filings matched on SEC CIK. Amounts are US$ as filed.
Peers in Life Sciences
| Ticker | Company | Exchange | Market cap (C$) | 1 month | 1 year |
|---|---|---|---|---|---|
| ACB | Aurora Cannabis Inc. | TSX | C$372.0M | +15.4% | +14.4% |
| PRN | Profound Medical Corp. | TSX | C$335.6M | +6.1% | +17.3% |
| WEED | Canopy Growth Corporation | TSX | C$393.7M | -25.0% | -47.1% |
| CPH | Cipher Pharmaceuticals Inc. | TSX | C$329.3M | +5.0% | +6.6% |
| PAIN | Vector Science and Therapeutics Corp. | TSXV | C$309.8M | +75.2% | Under a year of closes |
The app has the price chart, every filing, private raises and the full peer set for CL.
Open in the app